Medtronic LABS is expanding healthcare to patients battling non-communicable diseases in disadvantaged communities around the world
Northampton, MA –News Direct– Medtronic
No one ever wants to be so sick that they need hospital care. And yet, it took a trip to the hospital for 65-year-old “Kwasi” to finally get the care he needed for his diabetes and hypertension. While there, he was enrolled in a Medtronic LABS program that provides virtual care to patients in isolated areas of Kenya and Ghana. Now, when Kwasi checks his glucose and blood pressure, those readings are digitally relayed to his doctor, keeping him connected to his care. With his diabetes and hypertension under control, a healthy Kwasi says that checking his vital signs makes him happy.
A preventable tragedy
Like Kwasi, millions of people who live in underserved parts of the world suffer from chronic diseases. From hypertension to diabetes, chronic and non-communicable diseases are the leading cause of death worldwide, killing more than 41 million people each year. In many underserved countries, people die from non-communicable diseases simply because they lack access to quality healthcare. But access doesn’t always equal good outcomes for patients. Sometimes, the cost of treating non-communicable diseases can drain household resources, exacerbating the vicious cycle of poverty. Addressing the global threat of chronic disease will require a fundamental shift in the way healthcare is delivered. Technology can provide solutions that work for everyone.
Greater healthcare access for all
It all began with a challenge from Omar Ishrak, the former CEO of Medtronic. He asked: How might the Medtronic technological expertise be leveraged to expand access to healthcare for the five billion underserved patients across the world? The answer?
With more than 130 employees at 200+ sites across the globe, Medtronic LABS is an independent, non-profit organization with multiple entities including an operating foundation, a social business, and in-country subsidiaries that creates technology-powered healthcare solutions for disadvantaged communities around the world. Digital technology is at the core of these solutions, which can be scaled for maximum impact and efficiency.
By offering a combination of software, low-cost medical devices, and healthcare services, LABS is improving patient outcomes in some of the world’s most vulnerable and underserved communities.
To better understand the needs of these communities, LABS’ field operation experts, health coaches, clinicians, technologists, and designers work with local partners to remove barriers to quality healthcare such as cost, access, and social isolation. Whether it’s training community health workers in Africa or conducting hearing clinics in India, Medtronic LABS is creating equity within global health systems. But there’s more work to do.
Technology as a bridge to better health
The healthcare models created and scaled by Medtronic LABS capitalize on what Medtronic does best: applying cutting-edge technology to innovative medical devices, therapies, and healthcare solutions. These technology-fueled platforms are designed to meet patients where they are, often in their own communities. And by using remote technologies, Medtronic LABS is expanding the reach of clinicians in underserved communities where there are often shortages of medical professionals.
At the core of each of these technology platforms are data and analytics. Medtronic LABS helps patients capture data throughout the care continuum – during screening, enrollment, and throughout their entire healthcare journey. This wealth of data generated can be analyzed to inform care decisions and measure the program’s impact.
The software solutions developed by Medtronic LABS are designed to invest patients in their own healthcare. Patients can participate in virtual support groups or track their own data using customized dashboards. By giving patients tools like these, Medtronic LABS is helping to close pervasive healthcare gaps around the world.
A community presence
Medtronic LABS recognizes that a one-size-fits-all approach to healthcare won’t work in most disadvantaged communities. It relies on healthcare teams already integrated into local health systems to determine the best approach to deliver quality care. LABS trains these teams and local community health workers to provide screenings and ongoing management of chronic diseases.
A good example of Medtronic LABS’ hyperlocal approach to healthcare is currently unfolding in Bhutan. LABS is working with the government there, the UN Technology Bank, and other partners to screen children for hearing loss and provide continued care for those who need it. These screenings will take place at hospitals, schools, and communities across the country and utilize LABS portable screening and digital patient management technologies.
Expanding global access to healthcare requires perseverance and partners. Medtronic LABS has both. For example, LABS worked with the Kerala State Government to offer low-cost health services in public schools in India. During the pilot project, more than 1,100 school children were screened for hearing loss. In Kenya, LABS launched Afya Dumu, a landmark public-private partnership with the Ministry of Health, three county governments, Novartis Global Health, and Management Sciences for Health. Afya Dumu provides long-term support for patients with diabetes, hypertension, and other co-morbidities. In its first year, the partnership screened more than 20,000 people.
And now, for the first time, LABS is working to improve healthcare access for patients living in underserved communities in the United States. Recently, LABS announced collaborations with Medtronic, Virtua Health, and the Cherry Hill Free Clinic with the goal of helping patients manage their chronic diseases in Camden, NJ and beyond. The Cherry Hill Free Clinic will be the site of LABS’ first U.S.-based pilot. Together, the organizations aim to build a proven, replicable model that becomes the benchmark for community healthcare delivery across the United States.
Programs with purpose
Medtronic LABS is setting out to design the health system of the future — one that is equitable, tech-enabled, and patient-centered. Here’s how.
SHRUTI: Shruti, meaning ‘what is heard’ in Sanskrit, addresses ear diseases and hearing loss in underserved populations in India and Bhutan. It utilizes a community health worker (CHW)-based service model enabled by point-of-care diagnostics, hearing implants, and digital tools.
PRERNA: Prerna, meaning ‘inspiration’ in Sanskrit, is a comprehensive healthcare delivery model for people in India living with, or at risk for, Type 2 diabetes, hypertension, and co-morbid diseases in a group-based setting, close to home.
AFYA DUMU: Afya Dumu, meaning ‘lasting health’ in Swahili, is the result of a landmark public private partnership focused on creating a patient-centered, end-to-end model of care for patients living with chronic diseases in Kenya.
AKOMA PA: Akoma Pa, meaning ‘healthy heart’ in Twi, relies on a multi-stakeholder partnership to deliver transformative healthcare to people living with hypertension and diabetes in Ghana.
PADAYON AND SAKAM: Padayon, meaning ‘move forward’ in Hiligaynon, redefines patient experiences through innovative service delivery in the Philippines. Sakam takes a similar approach with patients in Cambodia.
Expanding the reach of doctors in Sub-Saharan Africa
As the COVID-19 pandemic reinforced, quality healthcare doesn’t always have to be delivered in-person. Patients enrolled in Medtronic LABS Empower Health program in Ghana and Kenya get the best of both worlds. They can receive virtual care from clinicians who can remotely review their data, provide feedback, and write prescriptions. Likewise, they can access regular blood pressure or glucose checks through community health workers at community partner locations or in the comfort of their own home.
Applying the power of technology to expand quality healthcare to underserved communities throughout the world is an ambitious, powerful goal. Patients enrolled in Medtronic LABS’ programs get the best of both worlds. By combining the passion and expertise of their people with Medtronic’s innovative medical technology, they are working to make the world a healthier, more equitable place for everyone.
Read the story.
View additional multimedia and more ESG storytelling from Medtronic on 3blmedia.com
View source version on newsdirect.com: https://newsdirect.com/news/how-medtronic-labs-is-expanding-healthcare-to-patients-around-the-world-623798363
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see ProAssurance…
It looks like Medtronic plc ( NYSE:MDT ) is about to go ex-dividend in the next 3 days. The ex-dividend date is usually…
The organizations plans to apply the latest research and innovation to the fundamentals of community-based care.
The wind energy stock, which has recently been languishing, picked up a rating upgrade from an analyst.
Biogen and its partner Eisai Co said they would seek a re-examination of the opinion given by the European Medicines Agency.
Inovio (INO) made a big splash last year with its Covid-19 DNA vaccine candidate INO-4800. Development, however, has been slow, and the vaccine is still a while away from entering the market, should it ever get that far. In the meantime, Inovio has been working on other, less headline grabbing candidates in its pipeline. On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le
Outstanding results for company's CAR-T therapy reported at ASH meeting
(Bloomberg) — New York state reported a one-day record of more than 21,000 infections as the omicron variant spreads in the U.S. Tests show a high rate of omicron transmission among Cornell University students.Most Read from BloombergAcross the U.S., School Shooting Threats on TikTok Prompt Closures and More PoliceSouth Africa Hospitalization Rate Plunges in Omicron WaveOmicron Gets Around Previous Covid Infection, Study WarnsSinopharm, J&J, Sputnik Vaccines Are Weaker Against Omicron in New St
Cannabis stocks turned in a weak performance in 2021 but the sector continues to grow as more U.S. states add to the adult-use market.
KENILWORTH, N.J. & MIAMI, December 17, /3BLMedia/ – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced the New England Journal of Medicin…
Omicron and new variants will dominate the Moderna stock conversation in 2022, experts say as shares yo-yo on fresh Covid news.
Pfizer said Friday it was changing plans and testing three doses of its COVID-19 vaccine in babies and preschoolers after the usual two shots didn't appear strong enough for some of the children.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for ObsEva SA's (NASDAQ: OBSV) linzagolix, an oral GnRH antagonist to manage moderate to severe symptoms of uterine fibroids. If approved, linzagolix would be the first and only approved GnRH receptor antagonist with a non-hormonal option to address the needs of women who cannot or do not want to take hormones. The positive opinion adopted is based on
Dr. Christopher Colbert, assistant program director of emergency medicine residency at University of Illinois, joins Yahoo Finance Live to discuss the latest trends he is seeing in the hospital and the purpose of vaccines.
Erica Romy, a nurse and body acceptance content creator, is using her platform to shed some light on her most-liked Instagram photos. The post TikToker reveals troubling truth behind her most-liked Instagram posts: ‘I don’t remember taking the photo’ appeared first on In The Know.
Pfizer and BioNTech will modify a clinical trial for their coronavirus vaccine in young children after a two-dose regimen did not produce a sufficient immune response.
Two years into the COVID-19 pandemic, many factors remain uncertain. Are we closer to the end of the pandemic than the beginning? What will be the ultimate impact of the newly discovered Omicron variant? What should we do about holiday gatherings? Definitive answers are in high demand but relatively short supply. Unless it comes to this COVID statistic. A brand-new study found that a certain group of people are 15 times more likely to die of COVID; it was preceded by a study that found the risk
The risk of reinfection with the Omicron coronavirus variant is more than five times higher and it has shown no sign of being milder than Delta, a study showed, as cases soar across Europe and threaten year-end festivities. The results of the study by Imperial College London were based on UK Health Security Agency and National Health Service data on people who tested positive for COVID-19 in a PCR test in England between Nov. 29 and Dec. 11. "We find no evidence (for both risk of hospitalisation attendance and symptom status) of Omicron having different severity from Delta," the study said, although it added that data on hospitalisations remains very limited.
The stock had been more than 1.5% higher, but slipped back into negative territory. Management had said the treatment might lose potency against the variant.
An influential advisory committee burnishes the reputations of the two companies' coronavirus vaccines, while one gets a glowing write-up about its COVID-19 pill.
‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort